genOway Opens Its First Franchises in Canada and Australia to Accelerate International Expansion
genOway announces the opening of its first two distribution franchises in Canada and Australia, marking a key milestone in its strategic plan ROUTE50+DATA. This initiative is part of the group's international business strategy aimed at expanding its presence in significant biopharmaceutical markets.
Launching Local Entrepreneur-Led Franchises
genOway continues its international expansion by establishing a model of 'genOway Franchises' entrusted to local entrepreneurs. Canada and Australia are hosting the first two franchises, with the ambition to rapidly increase sales. These franchises will initially capitalize on a base of historical clients before penetrating the main bioclusters of these markets. The first sales from these distribution contracts are expected as early as the third quarter of 2026. The genOway Franchise network is expected to contribute around 15% of revenues by 2028.
Expansion of the Franchise Network within a Broader Commercial Strategy
The development of the franchise network is part of a broader commercial plan. genOway is strengthening its sales teams in its priority markets (United States and major European countries) and is establishing new commercial subsidiaries to address large Asian markets (China, Japan, and India). This model is based on the strategic choice to rely on about ten distribution agreements tested over the past five years. The franchisees, equipped with a strong scientific background and deep market knowledge, will ensure the exclusive distribution of genOway's preclinical solutions.
